Correlation between blood activin levels and clinical parameters of type 2 diabetes

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Wu, Hui ^a   Wu, Michael ^a   Chen, Yi ^a   Allan, Carolyn A ^b   Phillips, David J ^a   Hedger, Mark P ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Paranta Biosciences   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVIN A; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLLISTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MYELOPID; SULFONYLUREA DERIVATIVE; ACTIVIN; BIOLOGICAL MARKER; FST PROTEIN, HUMAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BIOCHEMISTRY; BLOOD EXAMINATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE METABOLISM; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME;

ACTIVINS; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLISTATIN; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

MLCS; MLOWN;

EID: 84872144417     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/410579     Document Type: Article

References (39)

1. Shi H., Kokoeva M. V., Inouye K., Tzameli I., Yin H., Flier J. S., TLR4 links innate immunity and fatty acid-induced insulin resistance. The Journal of Clinical Investigation 2006 116 11 3015 3025 2-s2.0-33750584214 10.1172/JCI28898 (Pubitemid 44684486)
2. Sjoholm A., Nystrom T., Inflammation and the etiology of type 2 diabetes. Diabetes/Metabolism Research and Reviews 2006 22 1 4 10 10.1002/dmrr.568 (Pubitemid 43154455)
3. Fain J. N., Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitamins and Hormones 2006 74 443 477 2-s2.0-33846201363 10.1016/S0083-6729(06)74018-3
4. Hardy O. T., Perugini R. A., Nicoloro S. M., Gallagher-Dorval K., Puri V., Straubhaar J., Czech M. P., Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surgery for Obesity and Related Diseases 2011 7 1 60 67 2-s2.0-78751649211 10.1016/j.soard.2010.05.013
5. Plomgaard P., Bouzakri K., Krogh-Madsen R., Mittendorfer B., Zierath J. R., Pedersen B. K., Tumor necrosis factor- induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005 54 10 2939 2945 2-s2.0-25844456730 10.2337/diabetes.54.10.2939 (Pubitemid 41401090)
6. Wunderlich F. T., Luedde T., Singer S., Schmidt-Supprian M., Baumgartl J., Schirmacher P., Pasparakis M., Brüning J. C., Hepatic NF- B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 4 1297 1302 2-s2.0-39549101229 10.1073/pnas.0707849104 (Pubitemid 351397047)
7. Kewalramani G., Bilan P. J., Klip A., Muscle insulin resistance: assault by lipids, cytokines and local macrophages. Current Opinion in Clinical Nutrition and Metabolic Care 2010 13 4 382 390 2-s2.0-77954349550 10.1097/MCO.0b013e32833aabd9
8. Navarro-Gonzalez J., Mora-Fernandez C., Gomez-Chinchon M., Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration. International Journal of Immunopathology and Pharmacology 2010 23 1 51 59
9. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M., Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance. The Journal of Clinical Investigation 1995 95 5 2409 2415 2-s2.0-0028931724
10. Sun X., Han F., Yi J., Han L., Wang B., Effect of aspirin on the expression of hepatocyte NF- B and serum TNF- in streptozotocin-induced type 2 diabetic rats. Journal of Korean Medical Science 2011 26 6 765 770 2-s2.0-79958296379 10.3346/jkms.2011.26.6.765
11. Gupta-Ganguli M., Cox K., Means B., Gerling I., Solomon S. S., Does therapy with anti-TNF- improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care 2011 34 7 e121 e121 10.2337/dc10-1334
12. Phillips D. J., de Kretser D. M., Hedger M. P., Activin and related proteins in inflammation: not just interested bystanders. Cytokine and Growth Factor Reviews 2009 20 2 153 164 2-s2.0-63749105935 10.1016/j.cytogfr.2009.02. 007
13. Jones K. L., Mansell A., Patella S., Scott B. J., Hedger M. P., De Kretser D. M., Phillips D. J., Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proceedings of the National Academy of Sciences of the United States of America 2007 104 41 16239 16244 2-s2.0-36049023174 10.1073/pnas.0705971104 (Pubitemid 350099391)
14. Hashimoto O., Funaba M., Activin in glucose metabolism. Vitamins and Hormones 2011 85 217 234 2-s2.0-79951908000 10.1016/B978-0-12-385961-7.00011-1
15. Watanabe R., Activin receptor-like kinase and the insulin gene. Vitamins and Hormones 2011 85 1 27 2-s2.0-79951899292 10.1016/B978-0-12-385961-7.00001-9
16. Zhang Y. Q., Cleary M. M., Si Y., Liu G., Eto Y., Kritzik M., Dabernat S., Kayali A. G., Sarvetnick N., Inhibition of activin signaling induces pancreatic epithelial cell expansion and diminishes terminal differentiation of pancreatic β -cells. Diabetes 2004 53 8 2024 2033 2-s2.0-3242765289 10.2337/diabetes.53.8.2024 (Pubitemid 38970751)
17. Ogawa K., Funaba M., Chen Y., Tsujimoto M., Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. The Journal of Immunology 2006 177 10 6787 6794 2-s2.0-33750833717 (Pubitemid 44715043)
18. Dasu M. R., Devaraj S., Park S., Jialal I., Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010 33 4 861 868 2-s2.0-77953060025 10.2337/dc09-1799
19. Chen M. J., Chen H. F., Chen S. U., Ho H. N., Yang Y. S., Yang W. S., The relationship between follistatin and chronic low-grade inflammation in women with polycystic ovary syndrome. Fertility and Sterility 2009 92 6 2041 2044 2-s2.0-70749094391 10.1016/j.fertnstert.2009.06.009
20. Alberti K. G., Zimmet P. Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998 15 7 539 553 (Pubitemid 28319935)
21. Knight P. G., Muttukrishna S., Groome N. P., Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. Journal of Endocrinology 1996 148 2 267 279 2-s2.0-0030033697 (Pubitemid 26051528)
22. Ludlow H., Phillips D. J., Myers M., McLachlan R. I., De Kretser D. M., Allan C. A., Anderson R. A., Groome N. P., Hyvönen M., Colin Duncan W., Muttukrishna S., A new 'total' activin B enzyme-linked immunosorbent assay (ELISA): development and validation for human samples. Clinical Endocrinology 2009 71 6 867 873 2-s2.0-70449382483 10.1111/j.1365-2265.2009.03567.x
23. O'Connor A. E., McFarlane J. R., Hayward S., Yohkaichiya T., Groome N. P., De Kretser D. M., Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Human Reproduction 1999 14 3 827 832 2-s2.0-0032999372 (Pubitemid 29131271)
24. Friedewald W. T., Levy R. I., Fredrickson D. S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 6 499 502 2-s2.0-0015348189
25. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine 1999 130 6 461 470 2-s2.0-0033574249 (Pubitemid 29135798)
26. Chari S. T., Zapiach M., Yadav D., Rizza R. A., Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 2005 5 2-3 229 233 2-s2.0-19944404452 10.1159/000085276 (Pubitemid 40754742)
27. Tura A., Mari A., Winzer C., Kautzky-Willer A., Pacini G., Impaired β -cell function in lean normotolerant former gestational diabetic women. European Journal of Clinical Investigation 2006 36 1 22 28 2-s2.0-33645052180 10.1111/j.1365-2362.2006.01587.x
28. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation 2006 Geneva, Switzerland WHO Document Production Services
29. Standards of medical care in diabetes-2010. Diabetes Care 2010 33 supplement 1 S11 S61 10.2337/dc10-S011
30. Andersen G. Ø., Ueland T., Knudsen E. C., Scholz H., Yndestad A., Sahraoui A., Smith C., Lekva T., Otterdal K., Halvorsen B., Seljeflot I., Aukrust P., Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes 2011 60 5 1544 1551 2-s2.0-79959452702 10.2337/db10-1493
31. Weigert J., Neumeier M., Wanninger J., Schober F., Sporrer D., Weber M., Schramm A., Wurm S., Stögbauer F., Filarsky M., Schäffler A., Aslanidis C., Schölmerich J., Buechler C., Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. Cytokine 2009 45 2 86 91 2-s2.0-59249100306 10.1016/j.cyto.2008.10.017
32. Bodlaj G., Berg J., Pichler R., Sailer T., Biesenbach G., Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters. Journal of Nephrology 2004 17 1 112 117 2-s2.0-1842450546 (Pubitemid 38444637)
33. Lima L. M., Carvalho M. G., Soares A. L., Sabino A. D. P., Fernandes A. P., Novelli B. A., Sousa M. O., High-sensitivity C-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure. Arquivos Brasileiros de Endocrinologia e Metabologia 2007 51 6 956 960 2-s2.0-35848929444
34. Sjöholm K., Palming J., Lystig T. C., Jennische E., Woodruff T. K., Carlsson B., Carlsson L. M. S., The expression of inhibin beta B is high in human adipocytes, reduced by weight loss, and correlates to factors implicated in metabolic disease. Biochemical and Biophysical Research Communications 2006 344 4 1308 1314 2-s2.0-33646174632 10.1016/j.bbrc.2006.04.030
35. Ebert S., Phillips D. J., Jenzewski P., Nau R., O'Connor A. E., Michel U., Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. Journal of the Neurological Sciences 2006 250 1-2 50 57 2-s2.0-33750512122 10.1016/j.jns.2006.06.026 (Pubitemid 44665929)
36. Panunti B., Fonseca V., Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascular Pharmacology 2006 45 1 29 35 2-s2.0-33745490402 10.1016/j.vph.2005.11.013 (Pubitemid 43963483)
37. Hirai S., Yamanaka M., Kawachi H., Matsui T., Yano H., Activin A inhibits differentiation of 3T3-L1 preadipocyte. Molecular and Cellular Endocrinology 2005 232 1-2 21 26 2-s2.0-14344255768 10.1016/j.mce.2005.01.001 (Pubitemid 40292936)
38. Alessi M. C., Bastelica D., Morange P., Berthet B., Leduc I., Verdier M., Geel O., Juhan-Vague I., Plasminogen activator inhibitor 1, transforming growth factor- β 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000 49 8 1374 1380 2-s2.0-0033853610 (Pubitemid 30624239)
39. Dennler S., Itoh S., Vivien D., Dijke P. T., Huet S., Gauthier J. M., Direct binding of Smad3 and Smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. The EMBO Journal 1998 17 11 3091 3100 2-s2.0-0032101178 10.1093/emboj/17.11.3091 (Pubitemid 28254381)